RxDoctor Payments Data

Jessica Hanehan

Family · Troy, NYNPI 1932837325

Payments from drug & device makers

$1,038in general payments, 2019–2025

Across 34 payments — averaging $30.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$265
  • AbbVie$136
  • Actelion Pharmaceuticals US, Inc.$118
  • Verona Pharma, Inc.$104
  • GSK$65
  • AstraZeneca$63
  • plus $286 from 10 others

What the payments were for

  • Food & beverage$1,038100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,038 in reported general payments places this provider in the 70th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$30,886
Medicare patients
167
Services billed
508

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter152$162,510
Breztri AerosphereBudesonide/Glycopyr/Formoterol42$39,330
Breo ElliptaFluticasone/Vilanterol23$21,097
Incruse ElliptaUmeclidinium Bromide15$10,950
Albuterol Sulfate HfaAlbuterol Sulfate245$9,109
Fluticasone-SalmeterolFluticasone Propion/Salmeterol35$8,248
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$7,444
Advair HfaFluticasone Propion/Salmeterol11$6,507
BreynaBudesonide/Formoterol Fumarate14$4,795
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$3,671
SymbicortBudesonide/Formoterol Fumarate11$2,523
Prednisone202$603
Montelukast Sodium57$564
Azithromycin74$511
Omeprazole22$412

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta$65$202,002206 claims
AstraZenecaBreztri Aerosphere, Symbicort$63$41,85253 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,883 family providers in New York.

Other family in Troy

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →